[{"id":"4c6011fe-c4c1-44cd-84b3-1d40a184a9d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01545947","created_at":"2021-01-18T06:32:16.007Z","updated_at":"2024-07-02T16:36:53.837Z","phase":"Phase 1b","brief_title":"Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01545947","lead_sponsor":"Celgene","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • azacitidine • Onureg (azacitidine oral) • onatasertib (ATG-008)"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 05/01/2012","start_date":" 05/01/2012","primary_txt":" Primary completion: 12/11/2014","primary_completion_date":" 12/11/2014","study_txt":" Completion: 12/11/2014","study_completion_date":" 12/11/2014","last_update_posted":"2019-11-12"}]